{"id":1494,"date":"2026-06-17T15:00:00","date_gmt":"2026-06-17T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1494"},"modified":"2026-04-22T17:07:53","modified_gmt":"2026-04-22T17:07:53","slug":"gw501516-vs-gw0742-ppardelta-agonist-research-mechanisms-metabolic-studies","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/gw501516-vs-gw0742-ppardelta-agonist-research-mechanisms-metabolic-studies\/","title":{"rendered":"GW501516 vs GW0742: PPAR\u03b4 Agonist Research Mechanisms, Metabolic Studies &#038; Key Differences"},"content":{"rendered":"<!-- GW501516 vs GW0742: PPAR\u03b4 Agonist Research Mechanisms, Metabolic Studies & Key Differences -->\n<h1>GW501516 vs GW0742: PPAR\u03b4 Agonist Research Mechanisms, Metabolic Studies &amp; Key Differences<\/h1>\n\n<p>Among the nuclear receptors that regulate cellular energy metabolism, PPAR\u03b4 \u2014 peroxisome proliferator-activated receptor delta, also designated PPAR-beta\/delta \u2014 occupies a position of extraordinary interest for metabolic researchers. Its role in governing fatty acid oxidation, mitochondrial biogenesis, and skeletal muscle fiber type composition makes it a compelling target for studying how cells adapt to energy demand. Two synthetic PPAR\u03b4 agonists have shaped much of this research: GW501516 (widely known as Cardarine) and the structurally distinct GW0742. Understanding both compounds \u2014 their mechanisms, their divergent research histories, and their respective utility as molecular probes \u2014 is essential for any laboratory working in this space.<\/p>\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/gw501516-vs-gw0742-ppardelta-agonist-research-mechanisms-metabolic-studies\/#PPAR%CE%B4_Biology_The_Receptor_at_the_Center\" >PPAR\u03b4 Biology: The Receptor at the Center<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/gw501516-vs-gw0742-ppardelta-agonist-research-mechanisms-metabolic-studies\/#GW501516_Development_Mechanism_and_Discontinuation\" >GW501516: Development, Mechanism, and Discontinuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/gw501516-vs-gw0742-ppardelta-agonist-research-mechanisms-metabolic-studies\/#GW0742_A_Distinct_PPAR%CE%B4_Agonist_with_an_Alternative_Research_Profile\" >GW0742: A Distinct PPAR\u03b4 Agonist with an Alternative Research Profile<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/gw501516-vs-gw0742-ppardelta-agonist-research-mechanisms-metabolic-studies\/#AMPK-PPAR%CE%B4_Crosstalk_The_Signaling_Convergence\" >AMPK-PPAR\u03b4 Crosstalk: The Signaling Convergence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/gw501516-vs-gw0742-ppardelta-agonist-research-mechanisms-metabolic-studies\/#Comparing_the_Two_Compounds_Research_Applications_and_Limitations\" >Comparing the Two Compounds: Research Applications and Limitations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/gw501516-vs-gw0742-ppardelta-agonist-research-mechanisms-metabolic-studies\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"PPAR%CE%B4_Biology_The_Receptor_at_the_Center\"><\/span>PPAR\u03b4 Biology: The Receptor at the Center<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>PPAR\u03b4 is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. Upon ligand binding, it heterodimerizes with the retinoid X receptor (RXR), binds to PPAR response elements (PPREs) in target gene promoters, and recruits coactivator complexes that drive transcription. The downstream gene programs it activates are metabolically significant. Carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme for mitochondrial fatty acid import, is a canonical PPAR\u03b4 target. So is pyruvate dehydrogenase kinase 4 (PDHK4), which suppresses glucose oxidation \u2014 shifting cellular fuel utilization toward lipid substrates. ABCA1, a transporter mediating reverse cholesterol transport, is also regulated through this pathway.<\/p>\n\n<p>The net effect of robust PPAR\u03b4 activation is a transcriptional program oriented toward fat burning, mitochondrial expansion, and reduced glycolytic dependence. Why does this interest metabolic researchers? Because it provides a pharmacological lever to interrogate how cells make fuel selection decisions \u2014 and how those decisions relate to metabolic phenotypes in disease models.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"GW501516_Development_Mechanism_and_Discontinuation\"><\/span>GW501516: Development, Mechanism, and Discontinuation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>GW501516 was developed by GlaxoSmithKline as part of a systematic effort to create potent, selective PPAR\u03b4 agonists. It binds PPAR\u03b4 with high affinity \u2014 Ki approximately 1 nM \u2014 and activates PPAR\u03b4-driven transcriptional programs with exceptional potency and selectivity over the related receptors PPAR\u03b1 and PPAR\u03b3.<\/p>\n\n<p>Animal research produced striking results. In rodent models, GW501516 administration dramatically increased running endurance. The mechanism involved both acute metabolic shifts \u2014 increased fatty acid oxidation reducing glycogen depletion \u2014 and structural adaptations including skeletal muscle fiber type switching from glycolytic Type II toward oxidative Type I fibers. This fiber type transition is a slow biological process normally achieved through sustained endurance training, making its pharmacological induction through PPAR\u03b4 activation a remarkable research finding. The mechanistic question \u2014 precisely how PPAR\u03b4 drives fiber type gene programming \u2014 became a productive line of investigation.<\/p>\n\n<p>GW501516&#8217;s research trajectory changed fundamentally in 2007 when GlaxoSmithKline discontinued development. Preclinical safety studies had revealed rapid, multi-tissue tumor promotion in rats after only two weeks of exposure at high doses. This was not subtle carcinogenicity \u2014 the findings showed acceleration of tumor formation across multiple tissue types in a manner that raised serious mechanistic questions about what PPAR\u03b4 activation does in proliferating cell populations. Development ceased.<\/p>\n\n<p>That decision did not end scientific interest in GW501516 \u2014 far from it. The compound remains extensively used in basic metabolic research as a mechanistic probe, precisely because its PPAR\u03b4 potency and selectivity make it valuable for dissecting receptor biology in controlled experimental settings. The cancer findings are well-documented in the literature and inform how researchers design studies using this compound, with appropriate attention to dose, duration, and the biological context of proliferating versus quiescent cell models.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"GW0742_A_Distinct_PPAR%CE%B4_Agonist_with_an_Alternative_Research_Profile\"><\/span>GW0742: A Distinct PPAR\u03b4 Agonist with an Alternative Research Profile<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>GW0742 emerged as a structural alternative to GW501516 for PPAR\u03b4 research. Its binding affinity for PPAR\u03b4 is actually higher \u2014 pKi approximately 8.5 \u2014 reflecting its distinct chemical scaffold&#8217;s favorable interactions with the receptor&#8217;s ligand-binding pocket. Like GW501516, it activates the same core transcriptional program: CPT1, PDHK4, ABCA1, and related fatty acid oxidation targets.<\/p>\n\n<p>Why did researchers turn to GW0742? In part, because it offers a second, structurally independent tool to probe PPAR\u03b4 biology. Mechanistic conclusions are always strengthened when multiple chemically distinct compounds produce convergent results \u2014 it reduces the likelihood that findings reflect scaffold-specific off-target effects rather than genuine receptor-mediated biology. GW0742 provides that independent validation in PPAR\u03b4 research.<\/p>\n\n<p>GW0742 has generated its own interesting research literature, particularly in cardiac biology. Studies in cardiac ischemia models have examined its effects on mitochondrial function preservation during ischemia-reperfusion injury. The findings suggest PPAR\u03b4 activation may support mitochondrial integrity under energy-stressed conditions \u2014 a mechanistically distinct angle from the endurance\/fuel metabolism story that defined much of the GW501516 literature. This cardioprotective signaling research positions GW0742 as a tool for examining PPAR\u03b4&#8217;s role in cardiac energy metabolism specifically.<\/p>\n\n<p>The compound is also studied with interest as a potentially cleaner research tool for metabolic studies where GW501516&#8217;s cancer-association findings introduce interpretive complications \u2014 not because GW0742&#8217;s safety profile is established for any use outside research, but because its distinct chemistry allows researchers to examine whether biological effects are conserved across different PPAR\u03b4 agonist scaffolds.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"AMPK-PPAR%CE%B4_Crosstalk_The_Signaling_Convergence\"><\/span>AMPK-PPAR\u03b4 Crosstalk: The Signaling Convergence<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>One of the more mechanistically rich aspects of PPAR\u03b4 biology is its intersection with AMP-activated protein kinase (AMPK) signaling. AMPK is the cell&#8217;s primary energy sensor \u2014 activated when AMP\/ATP ratios rise, signaling energetic stress. It drives catabolic programs and suppresses anabolic ones. PPAR\u03b4 and AMPK appear to operate cooperatively in coordinating metabolic adaptation.<\/p>\n\n<p>The link runs through PGC-1\u03b1, the PPAR\u03b3 coactivator 1-alpha, which functions as a master regulator of mitochondrial biogenesis and is itself a PPAR\u03b4 coactivator. AMPK phosphorylates PGC-1\u03b1 at specific threonine and serine residues, activating it and amplifying mitochondrial gene programs. PPAR\u03b4, when activated by agonists such as GW501516 or GW0742, further engages PGC-1\u03b1 in transcriptional complexes at target gene promoters. The result is synergistic amplification of oxidative metabolic programming.<\/p>\n\n<p>This crosstalk means that researchers studying AMPK-PPAR\u03b4 interactions can use these agonists to ask precise mechanistic questions: Does PPAR\u03b4 activation require upstream AMPK phosphorylation of PGC-1\u03b1 for full transcriptional activation? Does AMPK-dependent and ligand-dependent PGC-1\u03b1 activation converge on identical or distinct gene programs? How does the interaction change in insulin-resistant versus insulin-sensitive cellular environments? These are productive, well-defined research questions that GW501516 and GW0742 help address as experimental tools.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Comparing_the_Two_Compounds_Research_Applications_and_Limitations\"><\/span>Comparing the Two Compounds: Research Applications and Limitations<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>GW501516 has a substantially larger published literature. Years of metabolic and exercise physiology research have used it to establish core findings about PPAR\u03b4-driven fatty acid oxidation and fiber type adaptation. This body of literature makes it the reference compound against which PPAR\u03b4 biology is often benchmarked.<\/p>\n\n<p>GW0742 offers structural independence and a somewhat distinct research application profile \u2014 with cardiac ischemia and mitochondrial stress models representing areas where it has generated notable findings. Its higher pKi may allow researchers to achieve comparable receptor engagement at lower concentrations in cell-based assays, potentially reducing complications from high-concentration non-specific effects.<\/p>\n\n<p>Both compounds carry important research limitations that laboratories must work around. GW501516&#8217;s tumor promotion findings mean it is used with particular attention to cellular proliferation status in model systems \u2014 rapidly dividing cell lines present a different context than quiescent primary cells or intact non-dividing tissue. GW0742&#8217;s more limited published literature means researchers must exercise greater caution in interpreting novel findings without the corroborating context available for GW501516. Neither compound should be considered interchangeable without experimental verification that the specific endpoints of interest respond consistently to both agonists in the model system being used.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>GW501516 and GW0742 together represent a research toolkit for interrogating PPAR\u03b4 biology from complementary angles. Their shared core mechanism \u2014 high-affinity PPAR\u03b4 binding, activation of fatty acid oxidation gene programs, AMPK-PGC-1\u03b1 crosstalk engagement \u2014 establishes them as tools for studying the same receptor while their structural and pharmacological differences offer independent validation opportunities. The scientific questions PPAR\u03b4 agonist research addresses are genuinely fundamental: How do cells switch between fuel sources? How does transcriptional regulation coordinate mitochondrial biogenesis? What role does PPAR\u03b4 play in cardiac energy homeostasis? For metabolic researchers asking these questions, these two compounds remain among the most powerful molecular probes available.<\/p>\n\n<p><em><strong>For Research Purposes Only:<\/strong> The information presented in this article is intended solely for scientific research and educational purposes. These compounds are not approved for human use and should only be handled by qualified researchers in appropriate laboratory settings in compliance with all applicable regulations.<\/em><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>A detailed scientific comparison of GW501516 (Cardarine) and GW0742, two PPAR\u03b4 agonists used in metabolic research. Covers receptor biology, fatty acid oxidation pathways, and AMPK-PPAR\u03b4 crosstalk.<\/p>\n","protected":false},"author":1,"featured_media":1564,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1494","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1494"}],"version-history":[{"count":1,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1494\/revisions"}],"predecessor-version":[{"id":1906,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1494\/revisions\/1906"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/1564"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}